10x Genomics stock
TXGNASDAQ10x Genomics, Inc., HealthcareISIN US88025U1097
43Score 43 out of 100, Weak
Price and trend
68 / 100
Price history
+254% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 39% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 40).
The price is 40% below its 52-week high. Largest decline in 7 years: 96% (April 2021 to April 2025).
Chart figures for advanced users
- SMA 50$74.02
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$42.39
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)40
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$15.46
- The lowest closing price of the last twelve months.
- Resistance$97.74
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- 10x Genomics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $7.73B, is number 50 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $642.82M (up 5.2% year on year) and a loss of $43.54M.
- For fiscal 2026, analysts expect on average revenue of $629.64M (down 2.1%) and adjusted earnings per share of −$0.63.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 498 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $575.68M, financial debt $75.79M.Stability 68
Weaknesses
- DilutionShare count up 23% since 2020.Capital allocation 19
- Loss-makingLoss of $67.08M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 76% a year over the last 12 months.Stability 68
Its standout strength is momentum, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
- high price swings
Valuation
Valuation signal
OvervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 3.6% on the twelve months before. Revenue has grown strongly since 2017, at around 32% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 69%, operating −17%, net −7%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 5 Nov 2026EPS reported −$0.15 (expected −$0.27)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 15.0% since 15 Oct 2026.
- Earnings per share
- −$0.63+15.0%
- Revenue
- $629.64M+1.4%
- Earnings per share
- −$0.67+3.9%
- Revenue
- $703.27M+3.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +9.6%2026 revenue outlook raised to $610 million to $630 million, while the expected shipments of about 40 Atera units remain unchanged.
“We are raising our full year outlook and now expect 2026 revenue to be in the range of $610 million-$630 million. Excluding non-recurring revenue related to patent litigation settlements in both 2026 and 2025, this represents 2%-5% growth over the full year 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $14.82M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Suliman ShehnaazSale
22 Sept 2026, Board
- Shares
- 5,723
- Price
- $81.19
- Value
- $464,668
- Saxonov SergeSale
22 Sept 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $81.22
- Value
- $2.03M
- Taich AdamSale
9 Sept 2026, Chief Financial Officer
- Shares
- 46,388
- Price
- $64.57
- Value
- $3M
Show 15 more
- Stuelpnagel John RSale
3 Sept 2026, Board
- Shares
- 20,000
- Price
- $61.75
- Value
- $1.24M
- Saxonov SergeSale
26 Aug 2026, Chief Executive Officer
- Shares
- 10,486
- Price
- $63.69
- Value
- $667,901
- Saxonov SergeSale
24 Aug 2026, Chief Executive Officer
- Shares
- 18,545
- Price
- $63.02
- Value
- $1.17M
- Taich AdamSale
24 Aug 2026, Chief Financial Officer
- Shares
- 17,166
- Price
- $63.02
- Value
- $1.08M
- Hindson Benjamin J.Sale
24 Aug 2026, See Remarks
- Shares
- 13,818
- Price
- $63.02
- Value
- $870,860
- Suliman ShehnaazSale
24 Aug 2026, Board
- Shares
- 2,207
- Price
- $63.65
- Value
- $140,478
- Teichmann Sarah A.Sale
14 Aug 2026, Board
- Shares
- 2,273
- Price
- $57.15
- Value
- $129,902
- Teichmann Sarah A.Sale
13 Aug 2026, Board
- Shares
- 5,278
- Price
- $57.29
- Value
- $302,377
- Stuelpnagel John RSale
11 Aug 2026, Board
- Shares
- 20,000
- Price
- $57.75
- Value
- $1.16M
- Saxonov SergeSale
22 Jun 2026, Chief Executive Officer
- Shares
- 30,000
- Price
- $34.44
- Value
- $1.03M
- Suliman ShehnaazSale
16 Jun 2026, Board
- Shares
- 5,723
- Price
- $32.63
- Value
- $186,756
- Saxonov SergeSale
26 May 2026, Chief Executive Officer
- Shares
- 10,718
- Price
- $24.71
- Value
- $264,833
- Saxonov SergeSale
22 May 2026, Chief Executive Officer
- Shares
- 18,175
- Price
- $24.44
- Value
- $444,224
- Hindson Benjamin J.Sale
22 May 2026, See Remarks
- Shares
- 11,595
- Price
- $24.44
- Value
- $283,399
- Taich AdamSale
22 May 2026, Chief Financial Officer
- Shares
- 15,098
- Price
- $24.44
- Value
- $369,018
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at 10x Genomics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- RemeGen688331.SS $8.26B44
- ALK-AbellóALK-B.CO $8.18B74
- AbivaxABVX.PA $8B35
- CytokineticsCYTK $7.82B33
- Rhythm PharmaceuticalsRYTM $7.62B41
- Axsome TherapeuticsAXSM $7.59B31
- Twist BioscienceTWST $7.52B46
- ImmunovantIMVT $7.25B45
ETFs that hold 10x Genomics
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 5.41% | 0.50% | €127.64M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.66% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.46% | 0.35% | €1.25B |
Show 5 more
| Harbor Health Care UCITS ETF AccW311 | 0.43% | 0.89% | €11.72M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.39% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.25% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.24% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.08% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 May 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.